Monitoring heart amyloidosis with a special scan
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at how a type of heart condition called transthyretin cardiac amyloidosis changes over time, using a special imaging test called a bone scan. The goal is to see if the scan can help track the disease and potentially improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years of age or older
- Diagnosed with transthyretin cardiac amyloidosis confirmed by a bone scan
- Able to provide signed consent
- Not have systemic AL amyloidosis
- Not be under legal guardianship or deprived of liberty
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing older adults with heart failure to see if a heart condition called cardiac amyloidosis (a buildup of abnormal protein in the heart) is present. If you are 80 or older, have been in the hospital for heart failure in the past year, and have a thickened heart wall, you may be able to join.
This study looks back at bone scans that were done for other reasons to see if they can spot a condition called cardiac amyloidosis, where abnormal protein builds up in the heart.
This study tests a faster type of bone imaging scan to help diagnose a rare heart condition where an abnormal protein builds up in the heart muscle. Researchers want to see if this newer imaging method works better than standard scans for detecting this condition.
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
This study uses a special PET scan tracer to see how consistent the images are in people with heart amyloidosis (a buildup of abnormal protein in the heart) and in people without the condition. The goal is to improve diagnosis and monitoring.
This study looks at how cardiac amyloidosis shows up on heart imaging, especially ultrasound (echocardiography). It may help doctors better describe and track the condition using your exam and test results.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.